Warm Springs Advisors Inc. Sells 96 Shares of Thermo Fisher Scientific Inc. $TMO

Warm Springs Advisors Inc. cut its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.4% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,906 shares of the medical research company’s stock after selling 96 shares during the quarter. Thermo Fisher Scientific makes up 1.4% of Warm Springs Advisors Inc.’s portfolio, making the stock its 22nd largest position. Warm Springs Advisors Inc.’s holdings in Thermo Fisher Scientific were worth $1,584,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of TMO. CBIZ Investment Advisory Services LLC grew its stake in Thermo Fisher Scientific by 137.5% in the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 33 shares in the last quarter. Anderson Financial Strategies LLC acquired a new stake in shares of Thermo Fisher Scientific in the 1st quarter valued at approximately $30,000. Keystone Global Partners LLC bought a new position in shares of Thermo Fisher Scientific in the first quarter valued at $31,000. DiNuzzo Private Wealth Inc. increased its holdings in Thermo Fisher Scientific by 406.7% during the second quarter. DiNuzzo Private Wealth Inc. now owns 76 shares of the medical research company’s stock worth $31,000 after buying an additional 61 shares during the last quarter. Finally, HighMark Wealth Management LLC lifted its stake in Thermo Fisher Scientific by 140.6% in the second quarter. HighMark Wealth Management LLC now owns 77 shares of the medical research company’s stock valued at $31,000 after acquiring an additional 45 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Wall Street Analysts Forecast Growth

TMO has been the topic of several recent analyst reports. Royal Bank Of Canada set a $561.00 price objective on shares of Thermo Fisher Scientific and gave the stock an “outperform” rating in a research note on Tuesday, September 2nd. TD Cowen upped their price objective on Thermo Fisher Scientific from $612.00 to $654.00 and gave the company a “buy” rating in a research note on Thursday, October 23rd. Wall Street Zen upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, October 25th. Argus increased their price target on Thermo Fisher Scientific from $580.00 to $610.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Finally, William Blair began coverage on Thermo Fisher Scientific in a report on Monday, August 18th. They set an “outperform” rating for the company. Nineteen analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $601.65.

Thermo Fisher Scientific Stock Down 0.2%

Shares of TMO opened at $566.47 on Friday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.11 and a current ratio of 1.50. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $610.97. The stock has a fifty day moving average of $516.99 and a 200-day moving average of $461.35. The stock has a market capitalization of $212.83 billion, a price-to-earnings ratio of 32.73, a PEG ratio of 3.27 and a beta of 0.82.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 EPS for the quarter, topping analysts’ consensus estimates of $5.50 by $0.29. The company had revenue of $11.12 billion for the quarter, compared to analyst estimates of $10.90 billion. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. Thermo Fisher Scientific’s revenue was up 4.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $5.28 earnings per share. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. As a group, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, January 15th. Stockholders of record on Monday, December 15th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend is Monday, December 15th. Thermo Fisher Scientific’s payout ratio is currently 9.94%.

Thermo Fisher Scientific declared that its board has authorized a share buyback plan on Thursday, November 6th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to reacquire up to 2.4% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s leadership believes its shares are undervalued.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 17,104 shares of the firm’s stock in a transaction on Friday, October 24th. The shares were sold at an average price of $573.54, for a total value of $9,809,828.16. Following the transaction, the chief executive officer directly owned 113,762 shares of the company’s stock, valued at approximately $65,247,057.48. This trade represents a 13.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction dated Friday, October 24th. The shares were sold at an average price of $574.15, for a total transaction of $229,660.00. Following the completion of the transaction, the executive vice president directly owned 21,152 shares in the company, valued at approximately $12,144,420.80. The trade was a 1.86% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 36,420 shares of company stock worth $19,980,884 in the last quarter. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.